

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

**(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING  
HELD ON JUNE 16, 2021;  
(2) CHANGE OF NON-EXECUTIVE DIRECTOR; AND  
(3) CHANGE IN COMPOSITION OF AUDIT COMMITTEE,  
REMUNERATION COMMITTEE AND THE ENVIRONMENTAL,  
SOCIAL AND GOVERNANCE COMMITTEE**

The board announces that:

- (1) at the AGM held on June 16, 2021, all proposed resolutions as set out in the notice of the AGM dated May 17, 2021 were duly passed by the relevant shareholders of the Company by way of poll;
- (2) Mr. Edward Hu retired as a non-executive Director with effect from the conclusion of the AGM and therefore he ceased to be a member of each of the Audit Committee and Remuneration Committee;
- (3) Dr. Ning Zhao has been appointed as a non-executive Director with effect from the conclusion of the AGM and was appointed as a member of each of the Remuneration Committee and the Environmental, Social and Governance Committee on the same date; and
- (4) Mr. Kenneth Walton Hitchner III was appointed as a member of the Audit Committee with effect from June 16, 2021.

## POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 16, 2021

The board (the “**Board**”) of directors (the “**Directors**”) of WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司\* (the “**Company**”) announces that at the annual general meeting of the Company (the “**AGM**”) held on June 16, 2021, all proposed resolutions as set out in the notice of the AGM dated May 17, 2021 were duly passed by the relevant shareholders of the Company by way of poll. Unless otherwise defined, terms used herein shall have the same meanings as those defined in the circular dated May 17, 2021 (the “**Circular**”).

The poll results taken at the AGM were as follows:

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and of the independent auditor of the Company for the year ended December 31, 2020.	3,167,541,424 (99.74%)	8,145,438 (0.26%)
2.	(a) To re-elect Mr. William Robert Keller as independent non-executive Director.	3,069,016,652 (97.35%)	83,455,144 (2.65%)
	(b) To re-elect Mr. Teh-Ming Walter Kwauk as independent non-executive Director.	3,019,225,155 (97.00%)	93,421,442 (3.00%)
3.	To elect Dr. Ning Zhao as non-executive Director.	2,250,647,760 (72.93%)	835,321,726 (27.07%)
4.	To authorise the Board or any duly authorised board committee to fix the Directors’ remuneration for the year ending December 31, 2021.	3,105,765,850 (98.59%)	44,556,355 (1.41%)
5.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditors and to authorise the Board or any duly authorised board committee to fix their remuneration.	3,122,962,014 (98.78%)	38,422,947 (1.22%)
6.	To grant a general mandate to the Directors to issue, allot and deal with the shares of the Company.	2,835,966,951 (90.14%)	310,123,444 (9.86%)

Ordinary Resolutions		Number of Votes (Approximate%)	
		For	Against
7.	To grant a general mandate to the Directors to repurchase the shares of the Company.	3,168,121,057 (99.76%)	7,566,055 (0.24%)
8.	To extend the general mandate granted to the Directors to issue, allot and deal with the shares of the Company by adding thereto the shares to be repurchased by the Company.	1,978,880,972 (64.21%)	1,103,191,556 (35.79%)
9.	To grant a specific mandate to the Directors to issue and allot the Connected Restricted Shares.	2,376,874,739 (76.41%)	733,971,196 (23.59%)
10.	To grant 945,200 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Dr. Zhisheng Chen.	2,372,073,810 (76.25%)	738,842,125 (23.75%)
11.	To grant 263,679 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Dr. Weichang Zhou.	2,372,073,810 (76.25%)	738,842,125 (23.75%)
12.	To grant 2,467 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Mr. William Robert Keller.	2,353,293,728 (75.52%)	762,980,207 (24.48%)
13.	To grant 4,934 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Mr. Teh-Ming Walter Kwauk.	2,353,985,329 (75.54%)	762,281,107 (24.46%)
14.	To grant 4,934 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Mr. Kenneth Walton Hitchner III.	2,353,985,328 (75.54%)	762,281,107 (24.46%)
15.	To grant 156,202 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Mr. Jian Dong.	2,372,073,810 (76.25%)	738,842,125 (23.75%)
16.	To grant 98,305 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Mr. Angus Scott Marshall Turner.	2,372,073,810 (76.25%)	738,842,125 (23.75%)
17.	To grant 17,420 Connected Restricted Shares pursuant to the Restricted Share Award Scheme to Mr. Brendan McGrath.	2,372,073,810 (76.25%)	738,842,125 (23.75%)

As at the date of the AGM, the total number of shares of the Company in issue, was 4,232,756,312 Shares.

As stated in the Circular, the respective Connected Grantees and their respective associates holding Shares were required to abstain and they had abstained from voting on the relevant resolutions numbered 9 to 17 in respect of the grant of Specific Mandate and the grant of Connected Restricted Shares to Connected Grantees proposed at the AGM.

To the best knowledge and belief of the Company, after making all reasonable enquiries, as at the date of the AGM, (i) Dr. Zhisheng Chen and his associates hold 10,235,405 Shares; (ii) Dr. Weichang Zhou and his associates hold 47,754 Shares; (iii) Mr. William Robert Keller and his associates hold 15,307 Shares; (iv) Mr. Teh-Ming Walter Kwauk and his associates hold 13,675 Shares; (v) Mr. Kenneth Walton Hitchner III and his associates hold 40,000 Shares; (vi) Mr. Jian Dong and his associates hold 33,260 Shares; (vii) Mr. Angus Scott Marshall Turner and his associates hold 1,183 Shares; and (viii) Mr. Brendan McGrath and his associates hold 1,714 Shares.

Accordingly, as at the date of the AGM, the respective total number of Shares entitling the holders to attend and vote on resolutions numbered 1 to 8 were 4,232,756,312 Shares, being the total number of issued Shares as at the date of the AGM, and on resolutions numbered 9 to 17 were 4,222,368,014 Shares, 4,222,520,907 Shares, 4,232,708,558 Shares, 4,232,741,005 Shares, 4,232,742,637 Shares, 4,232,716,312 Shares, 4,232,723,052 Shares, 4,232,755,129 Shares, and 4,232,754,598 Shares, respectively.

Save as disclosed above, there were no restrictions on any shareholders of the Company to cast votes on any of the resolutions proposed at the AGM. No shareholder of the Company has stated his/her/its intention in the Company's Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

The Company's Hong Kong branch share registrar, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM.

## **RETIREMENT OF NON-EXECUTIVE DIRECTOR**

Mr. Edward Hu did not offer himself for re-election of Director at the AGM as he wishes to devote more time to his other business commitments. Therefore, Mr. Hu retired from office as a non-executive Director upon conclusion of the AGM.

Mr. Hu has confirmed that there is no disagreement between him and the Board, and there are no matters relating to his retirement that need to be brought to the attention of the Shareholders or the Stock Exchange.

## APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is also pleased to announce that Dr. Ning Zhao has been appointed as a non-executive Director with effect from the conclusion of the AGM. The biographical details of Dr. Zhao are as follows:

Dr. Ning Zhao (趙寧), aged 54, is a co-founder and an executive director of WuXi AppTec Co., Ltd. (無錫藥明康德新藥開發股份有限公司) (“**WuXi AppTec**”), a company dual-listed on Shanghai Stock Exchange (上海證券交易所) (stock code: 603259) and the Main Board of the Stock Exchange (stock code: 2359). Since 2011, she has served as WuXi AppTec’s Senior Vice President of Operations and Global Head of Human Resources. In 2020, Dr. Zhao co-founded the Ge Li & Ning Zhao Family Foundation with Dr. Ge Li and serves as a director and president of the organization.

From 2004 to 2011, Dr. Zhao was the Vice President of Analytical Services and Lead Advisor of Analytical Services Operations at WuXi AppTec. In this role, she established WuXi AppTec’s global analytical services platform, which provides comprehensive and integrated capabilities across all stages of drug discovery and development. She previously held various research and management positions at Bristol-Myers Squibb, Pharmacoepia, and Wyeth Pharmaceuticals (now Pfizer).

Dr. Zhao is an Honorary Trustee of Peking University, and a member of the Board of Trustees at the Peddie School. She was named one of Forbes China’s “50 Top Women in Tech” in 2019, and to Forbes China’s “Top Businesswomen List” in 2021.

Dr. Zhao obtained her bachelor’s degree in chemistry from Peking University in 1989 and her doctoral degree in organic chemistry from Columbia University, where she was awarded the George Pegram Award, in 1995.

Saved as disclosed above, Dr. Zhao does not, at present, nor did she in the past three years, hold any directorship in any other public companies the securities of which are listed in Hong Kong or overseas.

Dr. Zhao has entered into a director’s service agreement with the Company for a term of three years which is terminable by either party with three months’ written notice, and she is subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the provision of the Articles of Association of the Company.

Dr. Zhao is a substantial shareholder of the Company and she is the spouse of Dr. Ge Li, the Chairman, non-executive Director and one of the substantial shareholders of the Company. Dr. Zhao entered into an acting-in-concert agreement dated June 30, 2016 with Dr. Ge Li, Mr. Zhaohui Zhang and Mr. Xiaozhong Liu to acknowledge and confirm their acting-in-concert relationship in relation to the Company. As at the date of this announcement, each of Dr. Zhao, Dr. Ge Li, Mr. Zhaohui Zhang and Mr. Xiaozhong Liu is a substantial shareholder of the Company. Saved as disclosed above, Dr. Zhao does not have any relationships with any other Directors or senior management, substantial shareholders or controlling shareholders of the Company.

As at the date of this announcement, Dr. Zhao was deemed to be interested in 732,535,133 Shares within the meaning of Part XV of the SFO.

Dr. Zhao is entitled to a director's remuneration of HK\$450,000 per annum, which is determined by the Board at the recommendation of the Remuneration Committee with reference to the prevailing market condition and her duties and responsibilities with the Company.

There is no information which is discloseable nor is/was Dr. Zhao involved in any of the matters required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to Dr. Zhao's election that need to be brought to the attention of the Shareholders and the Stock Exchange.

## **CHANGE IN COMPOSITION OF AUDIT COMMITTEE, REMUNERATION COMMITTEE AND THE ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE**

Subsequent to Mr. Edward Hu's retirement as a non-executive Director, he ceased to be a member of each of the Audit Committee and the Remuneration Committee with effect from June 16, 2021. The Board further announces that Dr. Ning Zhao was appointed as a member of each of the Remuneration Committee and the Environmental, Social and Governance Committee and Mr. Kenneth Walton Hitchner III was appointed as a member of the Audit Committee all with effect from June 16, 2021.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Hu for his valuable contributions to the Group during his tenure of office, and would like to extend its warmest welcome to Dr. Zhao on her new appointment.

For and on behalf of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, June 16, 2021

*As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.*

\* *For identification purpose only*